Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)

NCT04776655 is registered in ClinicalTrials.gov with Azienda USL Reggio Emilia - IRCCS as lead sponsor.

NCT NCT04776655
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04776655 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study in mCRC Patients With RAS/BRAF Wild Type Tissue and RAS Mutated in LIquid BIopsy to Compare in First-line Therapy FOLFIRI Plus CetuxiMAb or BevacizumaB (LIBImAb Study)
Lead sponsor
Azienda USL Reggio Emilia - IRCCS
Phase
Phase 3
Overall status
Active, not recruiting
Start date
April 30, 2021
Completion date
December 31, 2026
Enrollment
280 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer, metastatic colorectal cancer, ras mutation